SkQ1

Published

dm+d

Unassigned

New Medicines

VisomitinDry eye syndrome; moderate-to-severe

Information

Visomitin
New molecular entity
Not Known
Mitotech

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Reduces oxidative stress inside mitochondria, preserving them and improving dry eye. [2]
Dry eye syndrome is a common condition affecting 15-33% of those aged over 65 years. Prevalence increases with age. It is 50% more common in women than in men.[1]
Dry eye syndrome; moderate-to-severe
Topical